In the News December 8, 2023MYC drop: Synthetic lethal drugs are targeting a common cancer culpritRead MoreApril 4, 2023Anticancer Bioscience – Facilitating Cancer TreatmentRead MoreFebruary 11, 2023“We need to foster risky projects that can have large rewards”Read MoreAugust 1, 2022From Chengdu To The World: Anticancer Takes Novel Approach To Cancer Drug DevelopmentRead MoreFebruary 4, 2022Embrace new things and new ideas as curiosity drives creativity and innovationRead MoreJanuary 7, 2022Pharma’s Almanac Roundtable: For what therapeutic area do you think we will see the greatest progress in the coming years?Read MoreJanuary 7, 2022Pharma’s Almanac Roundtable: What do you see as the key innovations or technologies that will make personalized/precision medicine a reality?Read MoreOctober 25, 2021Anticancer Bioscience: A Precision Therapeutics Company Dedicated to Discovering and Developing Breakthrough Cancer Therapies for Unmet Oncology Needs Around the WorldRead MoreSeptember 4, 2021Treating Cancer with Novel Synthetic Lethal TherapiesRead MoreJuly 23, 2021Mini-library Approach Delivers an Arsenal in Drug Development PipelineRead MoreJuly 14, 2021Anticancer Bioscience appoints Dr. Hong Liu, as US-based VP of clinical developmentRead MoreJuly 14, 2021ACB hires Liu from Eureka Therapeutics to lead push into clinicRead MoreJune 14, 2021Anticancer Bioscience: applying synthetic lethality to MYC-driven cancersRead MoreJune 7, 2021Dun Yang – President & CEO, Anticancer BioscienceRead MoreMarch 25, 2021Synthetic lethal drugs vs. cancerRead MoreFebruary 9, 2021Anticancer Bioscience Raises $10M to Advance Synthetic Lethality ProgramsRead MoreFebruary 9, 2021China’s Anticancer Bioscience raises $10 million, aims high in ChinaRead MoreFebruary 8, 2021Anticancer Bioscience announces $10 million financingRead MoreFebruary 8, 2021A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate’s labRead More
